

# Sudden Cardiac Death & Chronic Kidney Disease



*"ESRD patients are prone to sudden death, stroke and myocardial infarction between dialysis sessions."<sup>1</sup>*

# Sudden Cardiac Death & Chronic Kidney Disease

## Sudden Cardiac Death

Sudden cardiac death (SCD) is defined as death from an unexpected circulatory arrest, occurring within an hour of the onset of symptoms, or an unwitnessed, unexpected death in patients known to be well within the previous 24 hours without an obvious non-cardiac cause.<sup>2</sup>

For the 20 million Americans that suffer from chronic kidney disease (CKD), SCD statistics are alarming. These CKD patients have a four to 20 times greater risk of sudden cardiac death (SCD) than do persons in the general population.<sup>3</sup> As their glomerular filtration rates decline indicating progressively lower kidney function, the risk of sudden cardiac death proportionally increases.<sup>2</sup>

Moreover, it is estimated that the number of patients with End-Stage Renal Disease (ESRD) on hemodialysis will reach one-half million by the year 2020.<sup>2,3</sup> Sudden death among these patients accounts for 25% of all causes of mortality.<sup>4</sup> In 1998, the American Journal of Kidney Disease underscored the gravity of this disease with the following title on the cover of their journal, "Cardiovascular Disease, An ESRD Epidemic."<sup>5</sup>

## Cardiovascular Collapse

Not only is cardiovascular disease (CVD) the leading cause of morbidity and mortality in patients with end-stage renal disease (ESRD), but cardiovascular collapse is a major cause of complications during a hemodialysis treatment. Congestive heart failure (CHF) in ESRD patients results from cardiac overload, anemia, severe hypertension and cardiac dysfunction. CVD mortality rates are about 30 times that of the general population, and in adolescents, CVD mortality rates are over 1,000 times that of their age-related peers.<sup>6</sup>

Multinational data from the Dialysis Outcomes and Practice Patterns (DOPPS) registry suggests that sudden death accounts for the highest proportion of hemodialysis deaths in the United States (33%) whereas lower proportions were observed in Japan (23%), Australia/New Zealand (19%) and Canada (18%).<sup>7</sup>

## Identifying SCD in CKD Patients

However, determining the sudden nature of death is problematic particularly among End-Stage Renal Disease (ESRD) patients because:

- Most sudden deaths among CKD patients are unwitnessed. Therefore, clinical information collected around that time is often limited
- ESRD patients are often chronically ill with comorbidities, and are frequently hospitalized.

## CKD Sudden Death Pathophysiology

In the general population, coronary heart disease that leads to ventricular fibrillation or sustained ventricular flutter is the major cause of sudden death.

In the case of CKD patients, studies suggest fundamental differences in the causes and pathology of sudden heart disease. In these patients, their coronary artery disease involves multi-vessel arterial stiffening and calcification rather than an ischemic myocardium that might trigger a terminal arrhythmia and death. Rather, CKD patients, especially those on hemodialysis, are subject to a wide array of potential arrhythmic triggers.

## When Does Sudden Death Occur

It has been observed that SCD in CKD occurs most frequently on days when hemodialysis is being administered, particularly on the first day after a three day weekend without dialysis.<sup>2</sup> Moreover, as illustrated in the graph below, the probability of sudden death increases in the time period immediately following dialysis.<sup>8</sup>

## Sudden Death Risks Factors

In ESRD patients on hemodialysis, an increased risk of SCD has been linked to:

- Rapid ultrafiltration rate
- Low calcium during hemodialysis
- Low potassium (hypokalemia) or high potassium (hyperkalemia) levels in the blood

*"Given the heightened risk of SCD in the CKD population and the abysmal long-term survival rate following a cardiac arrest, primary prevention of SCD should be a major priority."<sup>2</sup>*




Fig. 1: The graph illustrates the spike in the probability of sudden death immediately following dialysis. "35% of deaths occurred in the 1st 12-hour interval... 27% of these deaths occurred during dialysis and 33% occurred in the hour after the dialysis treatment (8)." Critically low CI levels (<2 L/min/m<sup>2</sup>) can occur in patients who do not feel well at the end of a dialysis session.

# Measure Cardiac Output — Save a Life!

*“The ability to monitor cardiac output is one of the important cornerstones of hemodynamic assessment ...in particular in patients with pre-existing cardiovascular comorbidities.”<sup>9</sup>*

## Proactive Patient Care

Cardiovascular complications in ESRD patients can be averted or reduced through periodic exams by the patient’s nephrologist, and routine screening of cardiac function with the Transonic HD03 Monitor.

## Cardiac Function Stressed

The rapid removal of large volumes of fluid during hemodialysis severely tests the limits of a patient’s cardiac function. Cardiac output decreases an average of 20% during the hemodialysis treatment causing less and less blood flow to be available to sustain the body’s vital functions. HD03 cardiac output measurements monitor a heart’s response to fluid removal during dialysis.

## Central Hemodynamic Profiling (CHP)

Cardiovascular parameters can change dramatically during dialysis. Therefore, multiple cardiac measurements are advised during a dialysis session for patients at risk for SCD in order to create a CHP (Fig. 5) to track the heart’s response to the stress of a dialysis treatment. CHP Monitoring identifies:

- Dramatic 20-30% CO drop during dialysis due to inaccurate dry weight estimation and/or medication that places patients at high risk for cardiovascular complications and sudden death following the dialysis session (Fig. 2).
- Prolonged high levels of access flow (>1,600-2,000 ml/min) that can lead to cardiomegaly and high output cardiac failure. This can be identified by an access flow to cardiac output ratio (AVF/CO) exceeding 25-30% (Fig. 3).
- Cardiac Index of <2 L/min/m<sup>2</sup>.




Fig. 2: Inadequate dry weight estimation increases the risk of cardiac failure.<sup>1,9</sup>




Fig. 3: One third of CO is redirected from the systemic circulation to the AV fistula placing patients at cardiac risk.




Fig.3: HD03 Hemodialysis Monitor displaying a CO screen.




Fig. 5: Central Hemodynamic Profiling (CHP): four measurements taken during a single hemodialysis session shows Cardiac Index responses to the hemodialysis treatment. Acceptable CI results range between 2.5 - 4.2 L/min/m<sup>2</sup>.

## Deterioration of CO & CI during Hemodialysis

Case Report, courtesy of Dr. T.A. Depner

Routine Flow-QC® Cardiac Function screening commenced 40 minutes into the hemodialysis session for a patient with ischemic heart disease. The first Cardiac Output measurement was 4.3 L/min with a Cardiac Index of 2.5. When the cardiac function test was repeated two hours later, the patient’s Cardiac Output had dropped to 2.7 L/min and his Cardiac Index was 1.6. The nephrologist was alerted, the patient’s hemodialysis prescription was adjusted, and his cardiac condition was closely monitored.



## References: Sudden Death & Chronic Kidney Disease

- Tucker T *et al*, "Unrecognized Deterioration of Cardiac Function during Hemodialysis," *J Am Soc Nephrol* 2002; 13: 213A
- Pun PH, "The interplay between CKD, sudden cardiac death, and ventricular arrhythmias," *Adv Chronic Kidney Dis.* 2014; 21(6): 480-8. (Transonic Reference # 10992R)
- U.S. Renal Data System. *USRDS 2007 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States.* Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2007.
- U.S. Renal Data System. *USRDS 2006 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States.* Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2006.
- Cardiovascular Disease — An ESRD Epidemic. *Am J Kid Dis* 1998; 32(5): Suppl 3.
- Locatelli F *et al*, "Cardiovascular Disease in Chronic Renal Failure; the Challenge Continues," *Nephrol Dial Transplant* 2000; 15(Suppl 5): 69-80. (Transonic Reference # HD9643R)
- Jadoul M *et al*, "Modifiable practices associated with sudden death among hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study," *Clin J Am Soc Nephrol.* 2012; 7(5): 765-74 (Transonic Reference # HD11010R)
- Bleyer AJ *et al*, "The Timing and Characteristics of Sudden Death in Hemodialysis Patients" *J Am Soc Nephrol* 2002; 13: SU-P0737.
- Tucker T *et al*, "Central Hemodynamic Profiling (CHP) during Outpatient Hemodialysis (HD)," *J Am Soc of Nephrol Abstr* 2002; 13: 209A. (Transonic Reference # HD268A)
- Krivitski NM, Depner TA, "Cardiac Output and Central Blood Volume during Hemodialysis: Methodology," *Adv Ren Replace Ther* 1999; 6(3): 225-232. (Transonic Reference # HD8T)
- Depner TA, Krivitski NM, "Central Blood Volume: A New Criterion for Predicting Morbid Events during Hemodialysis," *J Am Soc of Nephrol Abstr* 1996; 7(9) 1511. (Transonic Reference # HD15A)
- MacRae JM, "Vascular Access and Cardiac Disease: Is There a Relationship? *Curr Opin Nephrol Hypertens* 2006; 15(6): 577-82. (Transonic Reference # HD7382A)
- MacRae JM *et al*, "Arteriovenous Fistula-associated High-output Cardiac Failure: A Review of Mechanisms," *Am J Kidney Dis* 2004; 43(5): 17-22. (Transonic Reference # HD408A)
- Nikiforov UV *et al*, "Validation of a New Method to Measure Cardiac Output during Extracorporeal Detoxification," *ASAIO J* 1996; 42: M903-M905. (Transonic Reference # HD15V)
- Kislouchine VV, Dean DA, "Validation of a Novel Ultrasound Dilution Method to Measure Cardiac Output during Hemodialysis," *ASAIO J* 1996; 42: M906-M907. (Transonic Reference # HD16V)
- MacRae JM, "Vascular Access and Cardiac Disease: Is There a Relationship? *Curr Opin Nephrol Hypertens* 2006; 15(6): 577-82. (Transonic Reference # HD7382A)
- van der Mark WAMA *et al*, "Decreased access resistance in haemodialysis patients with upper arm arteriovenous fistulae," *Nephrol Dial Transplant.* 200; 23(6): 2105-6. (Transonic Reference # HD11002V)
- Mavrakanas TA, Charytan DM, "Cardiovascular complications in chronic dialysis patients," *Curr Opin Nephrol Hypertens* 2016; Sep 14, (Transonic Reference # HD10780R)
- Kanbay M *et al*, "Sudden cardiac death in patients with chronic kidney disease: prevention is the sine qua non," *Kidney Blood Press Res.* 2011; 34(4): 269-76. (Transonic Reference # HD10982R)
- Ranpuria R *et al*, "Unruh M. Heart rate variability (HRV) in kidney failure: measurement and consequences of reduced HRV," *Nephrol Dial Transplant.* 200; 23(2): 444-9. (Transonic Reference # HD10983R)
- Green D *et al*, "Sudden cardiac death in hemodialysis patients: an in-depth review," *Am J Kidney Dis.* 2011; 57(6): 921-9. (Transonic Reference # HD10985R)
- Wasse H, Singapur MS, "High-output Heart Failure: How to Define It, When to Treat It, and How to Treat It," *Semin Nephrol* 2012; 32(6): 551-7. (Transonic Reference # HD9868AHR)
- Makki N *et al*, "Do implantable cardioverter defibrillators improve survival in patients with chronic kidney disease at high risk of sudden cardiac death? A meta-analysis of observational studies." *Europace.* 2014; 16(1): 55-62. (Transonic Reference # HD10986R)
- Franczyk-Skóra B *et al*, "Prevention of sudden cardiac death in patients with chronic kidney disease," *MC Nephrol* 2012; 13:162. (Transonic Reference # HD10987R)
- Poulikakos D *et al*, "Risk of sudden cardiac death in chronic kidney disease," *J Cardiovasc Electrophysiol* 2014; 25(2): 222-31. (Transonic Reference # HD10988R)
- Alpert MA, "Sudden cardiac arrest and sudden cardiac death on dialysis: Epidemiology, evaluation, treatment, and prevention," *Hemodial Int.* 2011; 15 Suppl 1:S22-9. (Transonic Reference # 10989R)
- Shamseddin MK, Parfrey PS. "Sudden cardiac death in chronic kidney disease: epidemiology and prevention," *Nat Rev Nephrol*, 2011; 7(3): 145-54. (Transonic Reference # 10990R)
- Franczyk-Skóra *et al*, "Sudden cardiac death in CKD patients," *Int Urol Nephrol*, 2015; 47(6): 971-82. (Transonic Reference # 10993R)
- Bansal V, "Sudden Cardiac Death & Dialysis: Target Risk Factors," *Nephrology Times*, 2011; 4(8): 3-5. (Transonic Reference # 10994R)
- Assimon MM *et al*, "Ultrafiltration Rate and Mortality in Maintenance HD Patients," *Am J Kidney Dis*, 2016 Aug 26. (Transonic Reference # 10995R)
- Kramer H *et al*, "Ultrafiltration Rate Thresholds in Maintenance Hemodialysis: An NKF-KDOQI Controversies Report," *Am J Kidney Dis.* 2016; 68(4): 522-32P (Transonic Reference # )
- Banerjee D, "Sudden cardiac death in haemodialysis: clinical epidemiology and mechanisms," *J Electrocardiol* 2016 Jul 28 (Transonic Reference # HD10996R)
- Ramesh S *et al*, "Incidence of sudden cardiac death in adults with end-stage renal disease: a systematic review and meta-analysis," *BMC Nephrol*, 2016; 17(1): 78. (Transonic Reference # HD10997R)
- Di Lullo L *et al*, "Sudden cardiac death and chronic kidney disease: From pathophysiology to treatment strategies," *Int J Cardiol* 2016; 217: 16-27. (Transonic Reference # HD10998R)
- Basile C *et al*, "The impact of haemodialysis arteriovenous fistula on haemodynamic parameters of the cardiovascular system," *Clin Kidney J.* 2016; 9(5): 729-34. (Transonic Reference # HD11001A)
- Kiuchi MG, Mion D Jr., "Chronic kidney disease and risk factors responsible for sudden cardiac death: a whiff of hope? *Kidney Res Clin Pract.* 2016; 35(1): 3-9. (Transonic Reference # HD11004R)
- Potpara TS *et al*, "Cardiac Arrhythmias in Patients with Chronic Kidney Disease: Implications of Renal Failure for Antiarrhythmic Drug Therapy," *Curr Med Chem.* 2016; 23(19): 2070-83. (Transonic Reference # HD11005R)
- Pun PH *et al*, "Primary prevention implantable cardioverter defibrillators in end-stage kidney disease patients on dialysis: a matched cohort study. *Nephrol Dial Transplant.* 2015; 30(5): 829-35. (Transonic Reference # HD11007R)



www.transonic.com

Transonic Systems Inc. is a global manufacturer of innovative biomedical measurement equipment. Founded in 1983, Transonic sells "gold standard" transit-time ultrasound flowmeters and monitors for surgical, hemodialysis, pediatric critical care, perfusion, interventional radiology and research applications. In addition, Transonic provides pressure and pressure volume systems, laser Doppler flowmeters and telemetry systems.

### AMERICAS

Transonic Systems Inc.  
34 Dutch Mill Rd  
Ithaca, NY 14850  
U.S.A.  
Tel: +1 607-257-5300  
Fax: +1 607-257-7256  
support@transonic.com

### EUROPE

Transonic Europe B.V.  
Business Park Stein 205  
6181 MB Elsloo  
The Netherlands  
Tel: +31 43-407-7200  
Fax: +31 43-407-7201  
europe@transonic.com

### ASIA/PACIFIC

Transonic Asia Inc.  
6F-3 No 5 Hongsiang Rd  
Dayuan, Taoyuan County  
33747 Taiwan, R.O.C.  
Tel: +886 3399-5806  
Fax: +886 3399-5805  
support@transonicasia.com

### JAPAN

Transonic Japan Inc.  
KS Bldg 201, 735-4 Kita-Akitsu  
Tokorozawa Saitama  
359-0038 Japan  
Tel: +81 4-2946-8541  
Fax: +81 4-2946-8542  
japan@transonic.com